Close
  Indian J Med Microbiol
 

Figure 1: Receiver operating characteristic (ROC) curves of the various prostate-specific antigen (PSA) derivatives. ( a ) In the entire cohort ( n = 261); ( b ) in patients with tPSA at 2– 10 ng ml−1 ( n = 114); ( c ) in patients with tPSA at 10.1– 20 ng ml−1 ( n = 90); ( d ) in patients with tPSA > 20 ng ml−1 ( n = 54). tPSA: total PSA; %fPSA: free-to-total PSA ratio; PSAD: prostate-specific antigen density; p2PSA: [-2]proPSA; %p2PSA: p2PSA-to-free PSA ratio; PHI: Prostate Health Index.

Figure 1: Receiver operating characteristic (ROC) curves of the various prostate-specific antigen (PSA) derivatives. ( a ) In the entire cohort ( <i>n</i> = 261); ( b ) in patients with tPSA at 2– 10 ng ml<sup>−1</sup> ( <i>n</i> = 114); ( c ) in patients with tPSA at 10.1– 20 ng ml<sup>−1</sup> ( <i>n</i> = 90); ( d ) in patients with tPSA > 20 ng ml<sup>−1</sup> ( <i>n</i> = 54). tPSA: total PSA; %fPSA: free-to-total PSA ratio; PSAD: prostate-specific antigen density; p2PSA: [-2]proPSA; %p2PSA: p2PSA-to-free PSA ratio; PHI: Prostate Health Index.